Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Product/Service, Trade Show

Tranquis Therapeutics Presents Positive Preclinical Data on TQS-168 for the Treatment of ALS at Neuroscience 2021 Annual Meeting

Tranquis Therapeutics, a private immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases by reprogramming dysfunctional myeloid immune cells, today announced it presented positive preclinical data on its lead program TQS-168 at the Neuroscience 2021 meeting, which is the annual meeting of the Society for Neuroscience (SfN). This meeting is being held virtually November 8-11, 2021, with Preview Days taking place November 3-7. The data illustrate the potential of TQS-168 for the treatment of amyotrophic lateral sclerosis (ALS). TQS-168 showed increased median survival and decreased pro-inflammatory cytokines and inflammatory monocytes in a widely used SOD1-G93A transgenic mouse model and demonstrated a similar decrease in inflammatory monocytes in blood from ALS patients.

"These data provide convincing evidence that validates our unique approach of developing first-in-class therapeutics that target immune mediated CNS and non-CNS indications by reprogramming dysfunctional myeloid cells, and that our lead program has the potential to become a disease-modifying therapy that would benefit ALS patients," said Jonas Hannestad, MD, PhD, Chief Medical Officer and Head of R&D at Tranquis. "We believe TQS-168 represents a new class of treatment for ALS patients and these data paint a compelling picture which shows, in this preclinical model, a potential advance over approved treatments such as riluzole and edaravone. Based on these findings, we are rapidly advancing TQS-168 into Phase1 clinical studies to assess safety, pharmacokinetics, and pharmacodynamics."

While the pathogenesis of ALS is not fully understood, it's known that inflammation, including activation of myeloid cells, plays a key role and that pro-inflammatory cytokines and monocytes are hallmarks of disease progression.

Poster Presentation Details
Title: The small molecule myeloid cell modulator TQS-168 normalizes the inflammatory phenotype of immune cells from ALS patients and extends survival in the SOD1-G93A ALS mouse model
Presenter: Hope Lancero, Ph.D., Scientist, Tranquis Therapeutics
Date/Time: Tuesday Nov. 9, 2021 at 9:45 AM CT
Poster number: 2021-S-7606-SfN
Session: P230

Key Conclusions:
The effects of TQS-168 were evaluated in vivo in a SOD1-G93A murine model of ALS and ex vivo in blood samples from ALS patients. A 50-mg/kg dose of TQS-168 was administered three times per week in the SOD1-G93A murine model. Blood samples from patients with ALS were incubated for 4 hours at various concentrations of TQS-168.

About Tranquis

Tranquis Therapeutics is a breakthrough biopharmaceutical company focused on developing a portfolio of promising small molecule drugs with a unique mechanism of action, capable of reprogramming dysfunctional myeloid immune cells to revolutionize the management of a broad range of mitochondrial and immune mediated CNS and non-CNS indications and to significantly improve the lives of millions of patients. Founded on groundbreaking neuro-immunology research from the laboratory of Professor Edgar Engleman, MD, at Stanford University, Tranquis' novel therapies work by restoring normal mitochondrial biogenesis, cell homeostasis and function, effectively "switching" microglia and monocytes from a dysfunctional to a functional state by targeting master regulators of cell energy metabolism. For more information, visit www.tranquis.com.

These press releases may also interest you

at 17:55
Omeros Corporation today confirmed that earlier this month the company submitted to the U.S. Food and Drug Administration (FDA) its response to the Agency's Complete Response Letter (CRL) for narsoplimab in the treatment of hematopoietic stem cell...

at 17:43
Supermax Healthcare Canada wishes to clarify the circumstances and facts surrounding the decision, made with the Canadian government, to terminate the two contracts for the supply of nitrile gloves. At the outset, it is important to specify that the...

at 17:05
Seres Therapeutics, Inc. , a leading microbiome therapeutics company, today announced the publication in the New England Journal of Medicine (NEJM) of data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome...

at 17:00
Green Roads, a subsidiary of The Valens Company Inc.  ) (the "Company" "The Valens Company" or "Valens"), announces the launch of its first-ever brand campaign "Own the Day". The campaign celebrates Green Roads' products and their ability to help...

at 16:48
Note: All times local Ottawa, Ontario Private meetings The Prime Minister will receive a COVID-19 briefing from Chief Public Health Officer of Canada Dr. Theresa Tam. Closed to media   This document is also available at https://pm.gc.ca SOURCE Prime...

at 16:47

News published on 3 november 2021 at 12:10 and distributed by: